ストックスクリーナーアプリを入手
199.15
0.12%
0.24
アフターアワーズ：
199.15
前日終値:
$198.91
開ける：
$197.63
24時間の取引高:
1.11M
Relative Volume:
0.93
時価総額：
$29.40B
収益：
$9.60B
当期純損益:
$1.37B
株価収益率:
21.37
EPS:
9.3182
ネットキャッシュフロー:
$2.32B
1週間 パフォーマンス:
-7.85%
1か月 パフォーマンス:
+2.53%
6か月 パフォーマンス:
+6.15%
1年 パフォーマンス:
+47.16%
1日の値動き範囲:
$194.37
$199.98
1週間の範囲:
$194.37
$215.95
52週間の値動き範囲:
$121.05
$219.72
Biogen Inc Stock (BIIB) Company Profile
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
199.15 | 29.40B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,188.58 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | アップグレード | UBS | Neutral → Buy |
| 2026-04-20 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2025-11-06 | アップグレード | Stifel | Hold → Buy |
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026 - Biogen
Biogen stock reflects Alzheimer portfolio repositioning as neurology pipeline gains weight - ad-hoc-news.de
AstraZeneca's $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw - finance.biggo.com
Why is Biogen stock climbing today? By Investing.com - Investing.com Canada
Biogen Slides as Newly Disclosed Charges Pressure Near-Term Earnings - Moomoo
BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers - Stocktwits
Biogen's Q2 2026 Earnings: What to Expect - Yahoo Finance
Maria Elvira Salazar Makes Significant Trades in Biogen, Brookfield Renewable, and Salesforce - Investing.com
Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Morgan Stanley Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $222 - Moomoo
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $217 to $255 - Moomoo
BofA Securities Adjusts Biogen Price Target to $217 From $203 - marketscreener.com
Moderna adds former Biogen CFO to board of directors - Investing.com
Moderna adds former Biogen CFO to board of directors By Investing.com - Investing.com Canada
Former Biogen CFO Michael McDonnell joins Moderna (NASDAQ: MRNA) board and Audit Committee - Stock Titan
Moderna Appoints Michael McDonnell to Board of Directors - ACCESS Newswire
Moderna adds former Biogen CFO Michael McDonnell to its board - Stock Titan
Morgan Stanley Adjusts Price Target Biogen to $222 From $224, Maintains Equalweight Rating - marketscreener.com
Biogen (BIIB) Q1 2025 earnings summary - Quartr
symbol__ Stock Quote Price and Forecast - CNN
Biogen (BIIB) Research Report - StockStory
Spinraza from Biogen Inc.established SMA therapy faces biosimilar pressure - AD HOC NEWS
Biogen Inc. (BIIB) Securities Fraud InvestigationLevi & Korsinsky - AOL.com
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks - Endpoints News
Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Biogen Inc outlook for investors as biotech develops neurology pipeline - ad-hoc-news.de
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $255 - Moomoo
RBC Capital Adjusts Biogen Price Target to $242 From $227, Maintains Outperform Rating - marketscreener.com
Biogen to Webcast from the Alzheimer's Association International Conference (AAIC) July 14, 2026 - Biogen
Jefferies Adjusts Price Target on Biogen to $255 From $210 - marketscreener.com
Analyst recommendations: Ferguson, Medpace, Biogen, Crowdstrike, Take-Two… - marketscreener.com
Biogen Stock (BIIB) Opinions on Recent Earnings Charges and Analyst Upgrades - Moomoo
Biogen Inc (MEX:BIIB) Stock Price, Trades & News - GuruFocus
Biogen (BIIB) Hosts Webinar on ALS Research - GuruFocus
Biogen Inc (BIIB) Shares Fall 3.5% -- GF Value Says Still Overva - GuruFocus
How AAIC 2026 Alzheimer’s Data Releases Could Reframe Biogen (BIIB) Investors’ Long‑Term Thesis - simplywall.st
HSBC Adjusts Price Target on Biogen to $157 From $150 - marketscreener.com
Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida - GlobeNewswire Inc.
Biogen $18.9 Million Securities Class Action Settlement - Claim Depot
Biogen Inc. (BIIB): Investor Outlook On A Healthcare Giant With A $31.91 Billion Market Cap - DirectorsTalk Interviews
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now - Yahoo Finance
Biogen's $1 Billion Bet: A Venture-Style Pivot to Undisclosed Immunology - Kavout | AI
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors. - The Motley Fool
Biogen (BIIB) Could Be 1% Undervalued Before Key AAIC Alzheimer’s Data - simplywall.st
H.C. Wainwright Remains a Buy on Biogen (BIIB) - The Globe and Mail
BIIB News | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Is Biogen Inc (BIIB) Overvalued After 3.0% Rally? GF Value Says - GuruFocus
Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
BIIBBiogen Inc Latest SEC Filings - Finviz
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
0.33%
1.23%
大文字化:
|
ボリューム (24 時間):